Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seiya Okuda

Showing results (31-40 of 116) with videos related to

Pageof 12
Sort By:
Nihon Jinzo Gakkai Shi|September 1, 2005
[Steroid pulse therapy combined with tonsillectomy in a patient with IgA nephropathy complicated with tuberculous pleurisy]Kiyomi Koike, Kiyoshi Tamaki, Kazuhito Takeda, et al.
Journal of Diabetes and Its Complications|July 13, 2015
Serum albumin-adjusted glycated albumin reflects glycemic excursion in diabetic patients with severe chronic kidney disease not treated with dialysisKei Fukami, Ryo Shibata, Hitomi Nakayama, et al.
Viral Immunology|September 16, 2008
Detection of IgE antibody specific to a hepatitis C virus-derived peptide being recognized by cellular immunity in patients with HCV infectionShojiro Gohara, Shigeki Shichijo, Nobukazu Komatsu, et al.
Annals of Clinical Biochemistry|January 9, 2015
Serum albumin-adjusted glycated albumin is a better indicator of glycaemic control in diabetic patients with end-stage renal disease not on haemodialysisKei Fukami, Ryo Shibata, Hitomi Nakayama, et al.
Pharmacological Research|July 29, 2009
Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expressionTakanori Matsui, Sho-Ichi Yamagishi, Masayoshi Takeuchi, et al.
Expert Opinion on Investigational Drugs|June 14, 2008
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complicationsSho-Ichi Yamagishi, Kazuo Nakamura, Takanori Matsui, et al.
Clinical Nephrology|October 6, 2012
First reported case of collagenofibrotic glomerulopathy with a full-house pattern of immune depositsKei Fukami, Sho-Ichi Yamagishi, Tomohisa Minezaki, et al.
Biochemical and Biophysical Research Communications|May 23, 2009
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activationTakanori Matsui, Sho-ichi Yamagishi, Masayoshi Takeuchi, et al.
Thrombosis Research|February 1, 2015
Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 systemYuji Ishibashi, Takanori Matsui, Kei Fukami, et al.
Biochimica Et Biophysica Acta|March 29, 2011
Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetesSho-ichi Yamagishi, Sayaka Maeda, Takanori Matsui, et al.
Pageof 12

Showing results (31-40 of 116) with videos related to

Sort By:
Pageof 12
Nihon Jinzo Gakkai Shi|September 1, 2005
[Steroid pulse therapy combined with tonsillectomy in a patient with IgA nephropathy complicated with tuberculous pleurisy]Kiyomi Koike, Kiyoshi Tamaki, Kazuhito Takeda, et al.
Journal of Diabetes and Its Complications|July 13, 2015
Serum albumin-adjusted glycated albumin reflects glycemic excursion in diabetic patients with severe chronic kidney disease not treated with dialysisKei Fukami, Ryo Shibata, Hitomi Nakayama, et al.
Viral Immunology|September 16, 2008
Detection of IgE antibody specific to a hepatitis C virus-derived peptide being recognized by cellular immunity in patients with HCV infectionShojiro Gohara, Shigeki Shichijo, Nobukazu Komatsu, et al.
Annals of Clinical Biochemistry|January 9, 2015
Serum albumin-adjusted glycated albumin is a better indicator of glycaemic control in diabetic patients with end-stage renal disease not on haemodialysisKei Fukami, Ryo Shibata, Hitomi Nakayama, et al.
Pharmacological Research|July 29, 2009
Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expressionTakanori Matsui, Sho-Ichi Yamagishi, Masayoshi Takeuchi, et al.
Expert Opinion on Investigational Drugs|June 14, 2008
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complicationsSho-Ichi Yamagishi, Kazuo Nakamura, Takanori Matsui, et al.
Clinical Nephrology|October 6, 2012
First reported case of collagenofibrotic glomerulopathy with a full-house pattern of immune depositsKei Fukami, Sho-Ichi Yamagishi, Tomohisa Minezaki, et al.
Biochemical and Biophysical Research Communications|May 23, 2009
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activationTakanori Matsui, Sho-ichi Yamagishi, Masayoshi Takeuchi, et al.
Thrombosis Research|February 1, 2015
Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 systemYuji Ishibashi, Takanori Matsui, Kei Fukami, et al.
Biochimica Et Biophysica Acta|March 29, 2011
Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetesSho-ichi Yamagishi, Sayaka Maeda, Takanori Matsui, et al.
Pageof 12